
Flemming Saether
Examiner (ID: 23, Phone: (571)272-7071 , Office: P/3677 )
| Most Active Art Unit | 3677 |
| Art Unit(s) | 3679, 3675, 3627, 3751, 3508, 3677, 2899 |
| Total Applications | 3720 |
| Issued Applications | 2542 |
| Pending Applications | 266 |
| Abandoned Applications | 947 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17426779
[patent_doc_number] => 20220054487
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => METHODS FOR TREATING HETEROTOPIC OSSIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/413227
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7215
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413227
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/413227 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | Dec 12, 2019 | Abandoned |
Array
(
[id] => 16053061
[patent_doc_number] => 20200188385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => CRENOLANIB COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/713935
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713935
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/713935 | Crenolanib combination therapy | Dec 12, 2019 | Issued |
Array
(
[id] => 16898936
[patent_doc_number] => 20210177852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => TTP PHOSPHORYLATION AS A BIOMARKER IN TARGETED THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/710455
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710455
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/710455 | TTP phosphorylation as a biomarker in targeted therapy | Dec 10, 2019 | Issued |
Array
(
[id] => 16769720
[patent_doc_number] => 10980803
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
[patent_app_type] => utility
[patent_app_number] => 16/710495
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4363
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710495
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/710495 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Dec 10, 2019 | Issued |
Array
(
[id] => 16282539
[patent_doc_number] => 20200276141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/709805
[patent_app_country] => US
[patent_app_date] => 2019-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11466
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16709805
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/709805 | Compositions and methods for the treatment of cancer | Dec 9, 2019 | Issued |
Array
(
[id] => 17368202
[patent_doc_number] => 20220023254
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => ANTI-VIRAL COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/311031
[patent_app_country] => US
[patent_app_date] => 2019-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311031
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/311031 | Anti-viral composition | Dec 4, 2019 | Issued |
Array
(
[id] => 15738329
[patent_doc_number] => 20200108052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-09
[patent_title] => INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1
[patent_app_type] => utility
[patent_app_number] => 16/705135
[patent_app_country] => US
[patent_app_date] => 2019-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705135
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/705135 | Inhibitors of lysine specific demethylase-1 | Dec 4, 2019 | Issued |
Array
(
[id] => 15796989
[patent_doc_number] => 20200121637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS
[patent_app_type] => utility
[patent_app_number] => 16/700678
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700678
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700678 | Water soluble compositions comprising purified cannabinoids | Dec 1, 2019 | Issued |
Array
(
[id] => 15990349
[patent_doc_number] => 20200171045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => Neuroquiescence - A Treatment for Neurological and Nervous System Bioelectrical Dysregulation Associated with Seizures of Epilepsy
[patent_app_type] => utility
[patent_app_number] => 16/698444
[patent_app_country] => US
[patent_app_date] => 2019-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8350
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16698444
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/698444 | Neuroquiescence--a treatment for neurological and nervous system bioelectrical dysregulation associated with seizures of epilepsy | Nov 26, 2019 | Issued |
Array
(
[id] => 16183489
[patent_doc_number] => 10716782
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-21
[patent_title] => LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
[patent_app_type] => utility
[patent_app_number] => 16/692560
[patent_app_country] => US
[patent_app_date] => 2019-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 14595
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692560
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/692560 | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment | Nov 21, 2019 | Issued |
Array
(
[id] => 16703063
[patent_doc_number] => 10952976
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-23
[patent_title] => Compositions and methods for treating respiratory depression with fenfluramine
[patent_app_type] => utility
[patent_app_number] => 16/692968
[patent_app_country] => US
[patent_app_date] => 2019-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 13
[patent_no_of_words] => 15167
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16692968
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/692968 | Compositions and methods for treating respiratory depression with fenfluramine | Nov 21, 2019 | Issued |
Array
(
[id] => 17280841
[patent_doc_number] => 11197854
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-12-14
[patent_title] => Inhibitors for targeting flaviviruses
[patent_app_type] => utility
[patent_app_number] => 16/684445
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 19
[patent_no_of_words] => 19353
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684445
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684445 | Inhibitors for targeting flaviviruses | Nov 13, 2019 | Issued |
Array
(
[id] => 15990341
[patent_doc_number] => 20200171041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => METHODS AND THERAPEUTICS TO REGULATE HYDROGEN SULFIDE BIOAVAILABILITY
[patent_app_type] => utility
[patent_app_number] => 16/682209
[patent_app_country] => US
[patent_app_date] => 2019-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682209
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/682209 | Methods and therapeutics to regulate hydrogen sulfide bioavailability | Nov 12, 2019 | Issued |
Array
(
[id] => 16518652
[patent_doc_number] => 10869854
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-22
[patent_title] => Method for treating skin cancer
[patent_app_type] => utility
[patent_app_number] => 16/681379
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6566
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681379
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/681379 | Method for treating skin cancer | Nov 11, 2019 | Issued |
Array
(
[id] => 16053041
[patent_doc_number] => 20200188375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => Methods Of Treating Fabry Patients Having Renal Impairment
[patent_app_type] => utility
[patent_app_number] => 16/678183
[patent_app_country] => US
[patent_app_date] => 2019-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19780
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16678183
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/678183 | Methods of treating fabry patients having renal impairment | Nov 7, 2019 | Issued |
Array
(
[id] => 16954868
[patent_doc_number] => 11058695
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
[patent_app_type] => utility
[patent_app_number] => 16/677976
[patent_app_country] => US
[patent_app_date] => 2019-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 3980
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16677976
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/677976 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | Nov 7, 2019 | Issued |
Array
(
[id] => 17383785
[patent_doc_number] => 20220031637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION OR TRANSPLANT REJECTION DISEASES, COMPRISING NOVEL COMPOUND AND CALCINEURIN INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/290637
[patent_app_country] => US
[patent_app_date] => 2019-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290637
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290637 | Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor | Nov 6, 2019 | Issued |
Array
(
[id] => 15960111
[patent_doc_number] => 20200163807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => TAMPON WITH INTRAVAGINAL CANNABINOID DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 16/675346
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675346
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675346 | Tampon with intravaginal cannabinoid delivery device | Nov 5, 2019 | Issued |
Array
(
[id] => 15493053
[patent_doc_number] => 20200046715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => Medicament for Treating Peripheral Neuropathies
[patent_app_type] => utility
[patent_app_number] => 16/660802
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660802
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/660802 | Medicament for Treating Peripheral Neuropathies | Oct 22, 2019 | Abandoned |
Array
(
[id] => 16954860
[patent_doc_number] => 11058687
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Human papilloma virus as predictor of cancer prognosis
[patent_app_type] => utility
[patent_app_number] => 16/654582
[patent_app_country] => US
[patent_app_date] => 2019-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 30258
[patent_no_of_claims] => 49
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16654582
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/654582 | Human papilloma virus as predictor of cancer prognosis | Oct 15, 2019 | Issued |